The results showed that BC patients with higher MCU expression exhibited poorer overall survival (OS) (HR=1.40, 95% CI: 1.01-1.95, P=0.044; Figure 1A), distant metastasis-free survival (DMFS) (HR=1.86, 95% CI: 1.33-2.59, P=0.00024; Figure 1B), and relapse-free survival (RFS) (HR=1.22, 95% CI: 1.03-1.44, P=0.02; Figure 1D). The gene discussed is MCU; the disease is breast cancer.